CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹936 Cr | ₹634 Cr | ₹567 Cr | ₹743 Cr | ₹622 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹936 Cr |
| Mar2024 | ₹634 Cr |
| Mar2023 | ₹567 Cr |
| Mar2022 | ₹743 Cr |
| Mar2021 | ₹622 Cr |
How is Contingent Liabilities of CIPLA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹936 Cr | 47.65 | |
| Mar2024 | ₹634 Cr | 11.90 | |
| Mar2023 | ₹567 Cr | -23.73 | |
| Mar2022 | ₹743 Cr | 19.41 | |
| Mar2021 | ₹622 Cr | - | |
Compare Contingent Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹106,948.7 Cr | 0.7% | -11.2% | -6.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹382,694.0 Cr | -2.3% | -7.3% | -12.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹160,721.0 Cr | 0.8% | -5.8% | 4.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹134,016.0 Cr | 0.8% | 3.7% | 20.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,691.0 Cr | -1.4% | -3.8% | -1.3% | Stock Analytics | |
| MANKIND PHARMA | ₹87,717.0 Cr | 1.1% | -1.3% | -16.1% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 0.7% |
-11.2% |
-6.5% |
| SENSEX | -0.1% |
-2.9% |
7.5% |
You may also like the below Video Courses